| Description | Product Descriptionalpha-L-fucoside fucohydrolase, alpha-L-fucosidase, alpha-(1-3,4) fucosidaseAlpha (1-3,4) Fucosidase cleaves branched non-reducing terminal fucose, linked α(1-3) or α(1-4) to the N-acetylglucosamine of terminal Gal-GlcNAc disaccharide structures. The presence of sialic Product Descriptionalpha-L-fucoside fucohydrolase, alpha-L-fucosidase, alpha-(1-3,4) fucosidaseAlpha (1-3,4) Fucosidase cleaves branched non-reducing terminal fucose, linked α(1-3) or α(1-4) to the N-acetylglucosamine of terminal Gal-GlcNAc disaccharide structures. The presence of sialic acid (but not fucose) linked to the galactose will block cleavage.For removing core fucose linked α-(1-6) to the core GlcNAc of a GlcNAc-GlcNAc disaccharide structure we recommend our Alpha-(1-6) Fucosidase.α(1-3, 4) Fucosidase is useful for:nbsp;nbsp;Fucose linkage determinationnbsp;nbsp;Deglycosylating glycoproteins with Lewis structuresContentsAlpha-(1-3,4)-Fucosidase in 20 mM Tris-HCl, 25 mM NaCl,(pH 7.5).Included with 20 µL and 60 µL pack sizes:5x Reaction Buffer 5.0 (250 mM sodium phosphate, pH 5.0)Molecular weight40,000 daltonsFormulationThe enzyme is provided as a sterile-filtered solution in 20 mM Tris-HCl, 25 mM NaCl pH 7.5.Suggested usage1. Add up to 1 nmole of oligosaccharide to a tube.2. Add de-ionized water to a total of 15 µl.3. Add 4 µl of 5x Reaction Buffer 5.0.4. Add 1 µl of Alpha-(1-3,4)-Fucosidase.5. Incubate for 1 hour at 37˚C.SpecifictityNon-reducing terminal branched fucose when linked alpha-(1-3) or alpha-(1-4) to GlcNAc of a Gal-GlcNAc disaccharide structure. The presence of sialic acid (but not fucose) linked to the galactose will block cleavage.Specific Activity AssayOne unit of Fucosidase activity is defined as the amount of enzyme required to cleave 1 µmole of fucose from Lewis X trisaccharide, 4-methylumbelliferyl glycoside in 1 minute at 37˚C and pH 5.0. Lewis X trisaccharide is Gal Beta-(1-4)[Fuc alpha-(1-3)]GlcNAc.PurityEach lot of α(1-3, 4) Fucosidase is tested for contaminating activities by incubating the enzyme for 24 hours at 37°C with the appropriate substrates; the detection limit of this assay is 5 µU/mL (IUB). A passing lot will have no detectable activity.For the protease assay, 10 µg of denatured BSA is incubated for 24 hours with 2 µL of enzyme. Analysis of the BSA band after SDS-PAGE should show no evidence of degradation.StabilityStable at least 12 months when stored properly. Several days exposure to ambient temperatures will not reduce activity... Read More | description：Bovine pancreatic deoxyribonuclease I produced recombinantly in yeast, Pichia pastoris, to decrease levels of contaminating RNase and eliminate potential pathogens associated with animal based materials.Bovine pancreas is a rich source of RNase A which is often found in many description：Bovine pancreatic deoxyribonuclease I produced recombinantly in yeast, Pichia pastoris, to decrease levels of contaminating RNase and eliminate potential pathogens associated with animal based materials.Bovine pancreas is a rich source of RNase A which is often found in many commercial DNase preparations. Producing DNase I by recombinant means in an organism with much lower levels of endogenous RNase greatly facilitates purification of an enzyme with undetectable levels of RNase. The processes involved in the production and isolation of recombinant DNase I are completely devoid of animal based components which eliminates the possibility of introducing animal derived pathogens into bioprocessing procedures.Animal Free/AF. Recombinant Bovine pancreatic deoxyribonuclease 1 produced in Pichia pastoris. Chromatographically purified. Free of animal derived components, RNases & proteases. A liquid preparation in 5mM Calcium Acetate, 4mg/ml glycine, pH 5.0 and 50% glycerol. Supplied with 10x reaction buffer.Storage Buffer : 5mM calcium acetate, 4mg/ml glycine, pH 5.0 and 50% glycerol.DNase I Reaction Buffer (10X): 500mM Tris-HCl, 10mM MgSO4, 1mM CaCl2, pH 7.8, provided.application：Recombinant DNase I is suitable for such applications as:• Removing genomic DNA from RNA preparations prior to RT-PCR• Degradation of DNA templates after transcription reactions• Removing unwanted DNA from samples prior to Northern blotting• Removing DNA during biopharma and bioprocessing procedures... Read More | InformationMyelin Oligodendrocyte Glycoprotein 35-55, mouse, rat (MOG 35-55) is a minor component of CNS myelin that induces experimental autoimmune encephalomyelitis in C57BL/6 mice by an encephalitogenic T cell response | Inquire | Purity>97% SDS-PAGE and HPLC analyses. FunctionLA-PF4 stimulates DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and synthesis of hyaluronic acid and sulfated glycosaminoglycan. It also stimulates the formation and secretion of plasminogen Purity>97% SDS-PAGE and HPLC analyses. FunctionLA-PF4 stimulates DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and synthesis of hyaluronic acid and sulfated glycosaminoglycan. It also stimulates the formation and secretion of plasminogen activator by human synovial cells. NAP-2 is a ligand for CXCR1 and CXCR2, and NAP-2, NAP-2(73), NAP-2(74), NAP-2(1-66), and most potent NAP-2(1-63) are chemoattractants and activators for neutrophils. TC-1 and TC-2 are antibacterial proteins, in vitro released from activated platelet alpha-granules. CTAP-III(1-81) is more potent than CTAP-III desensitize chemokine-induced neutrophil activation.Post-translationalProteolytic removal of residues 1-9 produces the active peptide connective tissue-activating peptide III (CTAP-III) (low-affinity platelet factor IV (LA-PF4)). Proteolytic removal of residues 1-13 produces the active peptide beta-thromboglobulin, which is released from platelets along with platelet factor 4 and platelet-derived growth factor. NAP-2(1-66) is produced by proteolytical processing, probably after secretion by leukocytes other than neutrophils. NAP-2(73) and NAP-2(74) seem not be produced by proteolytical processing of secreted precursors but are released in an active form from platelets... Read More |